NCT03576183View on ClinicalTrials.gov

Study Confirming A Human Challenge Model and Investigating The Safety Of VLA1701

PHASE2CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

June 4, 2018

Primary Completion Date

June 26, 2018

Study Completion Date

November 30, 2018

Conditions
Enterotoxigenic Escherichia Coli InfectionDiarrhea
Interventions
BIOLOGICAL

VLA1701

VLA1701 is an investigational oral vaccine against LT-ETEC (Labile Toxin-Enterotoxigenic E coli)

BIOLOGICAL

Placebo

buffer component of VLA1701

OTHER

Challenge Strain

LSN03-016011/A

Trial Locations (1)

21205

Department of International Health Johns Hopkins University, Baltimore

Sponsors
All Listed Sponsors
collaborator

Johns Hopkins University

OTHER

collaborator

Naval Medical Research Center

FED

lead

Valneva Austria GmbH

INDUSTRY

NCT03576183 - Study Confirming A Human Challenge Model and Investigating The Safety Of VLA1701 | Biotech Hunter | Biotech Hunter